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Abstract  
AIM: To investigate the association of peroxisome proliferator-activated receptor gamma (PPARG) Pro12Ala 
polymorphism with polycystic ovary syndrome (PCOS) and its effect on the metabolic parameters in PCOS 
women. 
METHODS: The study used PCR to identify the presence of the PPARG Pro12Ala polymorphism in 100 PCOS 
women and 120 age-matched healthy women. All participants were subjected to anthropometry, biochemical and 
metabolic evaluation.  
RESULTS: Significant difference in the genotypes distributions of PPARG Pro12Ala polymorphism was observed 
among PCOS women and controls (p = 0.03). The frequency of the polymorphic allele Ala was significantly higher 
in PCOS cases than that in the controls (OR = 2.01, p = 0.01). The carries of the variant allele Ala in PCOS 
women showed significant higher values in body mass index (BMI), systolic and diastolic blood pressure, waist 
circumference, waist to hip ratio, sum of skin folds, fasting blood glucose, fasting blood insulin, HOMA-IR, fasting 
triglycerides, total cholesterol and low-density lipoprotein than non-carriers.  
CONCLUSION: The PPARG Pro12Ala polymorphism might contribute to the risk of PCOS and abnormal 
metabolic parameters and could be considered as a biomarker for early diagnosis and clinic prediction of 
metabolic complications. 
 
 
 
 
 
Introduction 
 
Insulin sensitivity might be regulated by the 
peroxisome proliferator-activated receptor gamma 
(PPARG). The PPARG gene product regulates 
glucose and lipid metabolism as it plays a substantial 
role in the energy storage management and insulin 
sensitivity [1]. It is expressed in adipose tissue, 
macrophages, intestines and ovaries and supposed to 
be involved in polycystic ovary syndrome (PCOS) risk 
[2]. 
It is known that the prevalence of PCOS is 
about 5–10 % among women in the reproductive age 
and cases are frequently diagnosed during 
adolescence [3]. PCOS is associated with different 
degrees of hormonal and metabolic disturbances [4]. 
In addition, high prevalence of women with PCOS are 
susceptible to gaining weight and showing phenotype 
with metabolic abnormalities such as insulin 
resistance, compensatory hyperinsulinemia [5], risk 
for diabetes mellitus type 2 (T2DM) [6] and 
cardiovascular diseases (CVD) [7] (Hosoya et al., 
2000). The development of PCOS is due to 
interactions of multiple genetic and environmental 
factors that are involved in its occurrence and 
complications [5].  
However, the exact pattern of inheritance still 
needs to be more clarified. The PPARG gene plays a 
role in the regulation of insulin sensitivity and lipid 
metabolism [8]. It might be involved in insulin action 
and secretion, energy metabolism, adiposity [1] and 
also implicated in the pathogenesis of PCOS.  
Our goal in this study was to explore the 
possible association that might present between the 
PPARG Pro12Ala polymorphism and PCOS risk and 
abnormal metabolic parameters.  
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Patients and Methods 
 
This study was designed as a case-control 
study including 100 women with PCOS between 20-
30 years of age and 120 age-matched healthy female 
controls. All the procedures used in this study were by 
the guidelines of the Helsinki Declaration on Human 
Experimentations. The study was approved by local 
ethics committee of the National Research Centre 
(No: 13176); the purpose of the protocol was 
explained to the women, and written informed consent 
was obtained from them before beginning the study. 
They were referred from different centres to the 
National Research Centre obesity clinic between 2013 
and 2014. Polycystic ovaries were diagnosed by 
pelvic or transvaginal sonography according to the 
Rotterdam Conference criteria [9].  
 
DNA extraction and genotyping 
From each participant, 5 mL of venous blood 
sample was taken. To examine the Pro12Ala 
polymorphism in exon 2 of PPAR-c, genomic DNA 
was extracted from peripheral whole-blood samples 
(QIAamp DNA Blood Mini Kit; (QIAGen GMbH 
Germany, Dusseldorf, Germany). 
Each reaction mixture was 25 µL in volume, 
comprising (100 ng/µL) DNA, 2 U Taq polymerase 
(Thermo Scientific Fermetas, USA), 0.2 mmol/L 
dNTPs, 0.5 mmol/L of each primer, PCR buffer 
(containing 1 mmol/L Tris HCL and 50 mmol/LKCL) 
and 1.5 mmol/L MgCl2. The primers sequence were 
5'-GCCAATTCAAGCCCAGTC-3' for the forward and 
5'-GATATGTTTGCAGACAGTGTATCAGTGAAGGAA 
TCGCTTTCCG-3' for the mutagenic reverse primer as 
described by Yilmaz et al. 2006 [10]. 
PCR was performed with an initial 
denaturation at 94°C for 5 min, followed by 35 cycles 
of denaturation at 94°C for 30 s annealing at 65°C for 
45 s and extension 72°C for 10 min. The amplified 
fragment of 270 bp was treated with the restriction 
enzyme BstUI, which resulted in digestion of the PCR 
product into two fragments of 227 and 43 bp in length 
if the polymorphic site had the G allele (Ala), while the 
PCR amplicon remained uncut in the presence of the 
C allele (Pro). The digested product was separated on 
a 3% agarose gel stained with ethidium bromide. The 
wild-type allele resulted in a fragment of 270 bp while 
the mutant allele resulted in two fragments of 227 bp 
and 43 bp.  
 
Anthropometry and blood pressure 
Body weight, height, mid-upper arm 
circumference, waist and hip circumferences and skin 
fold thickness biceps, triceps and subscapular, supra 
iliac and abdominal skin fold thickness were 
measured. All measurements were taken 3 times on 
the left side of the body, and the mean of the 3 values 
was used. Body weight was measured to the nearest 
0.1 kg and height was measured to the nearest 0.1 
cm. Height was measured with the patients standing 
with their backs leaning against the stadiometer of the 
same scale. Body mass index (BMI) was calculated 
as weight in kilogrammes divided by height in meters 
square (kg/m^2). Mid-upper arm circumference 
(MUAC) was measured using a flexible tape at the 
midway between the olecranon and acromial process 
on the upper right arm with the elbow flexed 90 
degrees. Waist circumference (WC) and hip 
circumference (HC) were measured in cm using a 
plastic, non-stretchable tape. WC was measured with 
light clothing at a level midway between the lower rib 
margin and the iliac crest standing and breathing 
normally. HC was measured at the level at the widest 
circumference over the buttocks (at the greater 
trochanter). Waist to hip ratio (WHR) was calculated. 
Skin-fold thickness was measured to the nearest mm, 
except for low values (usually 5 mm or less) when it 
was taken to the nearest 0.5 mm. These readings 
were made at six sites on all subjects, at the biceps, 
triceps, subscapular and supra-iliac areas, using 
Holtain calliper (Ltd, Bryberian, Crymmych, 
Pembrokeshire). The subscapular skinfold was 
measured below the lower angle of the left scapula at 
a diagonal in the natural cleavage of the skin. Biceps 
was measured at the level of the midpoint between 
the acromion (lateral edge of the acromion process) 
and the radius (proximal and lateral border of the 
radius bone) on the mid-line of the anterior surface of 
the arm, triceps (vertical fold, midway between 
acromion and olecranon processes on the posterior 
surface of the arm), and the position of the supra iliac 
skinfold was the diagonal fold just above the iliac crest 
even with the anterior axillary line, abdominal skin fold 
was at 5 cm adjacent to the umbilicus to the right side. 
Subsequently, sum of skin folds was calculated. 
Anthropometric measurements were obtained 
according to standardized equipment and following 
the recommendations of the International Biological 
Program [11]. Systolic and diastolic blood pressures 
(SBP and DBP) were measured twice in the right arm 
in a sitting position after a 10 min rest period; using a 
mercury sphygmomanometer the average of the two 
measurements was used for analysis. Blood pressure 
was measured according to a standardized operating 
procedure using a calibrated sphygmomanometer and 
brachial inflation cuff (HEM-7200 M3, Omron 
Healthcare, Kyoto, Japan). 
 
Laboratory measurements 
Venous blood samples were collected by 
direct venipuncture after an overnight fast (minimum 
12 h). Fasting plasma glucose and serum lipids (total 
cholesterol, high-density lipoprotein cholesterol (HDL-
C) triglycerides (TG) were measured by enzymatic 
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colorimetric methods using a Hitachi autoanalyzer 704 
(Roche Diagnostics. Switzerland) [12].  
Low-density lipoprotein cholesterol (LDL-C) 
was calculated according to certain equation (LDL-C= 
Total cholesterol –Triglycerides/5+ HDL-C) [13]. 
Serum insulin concentration was analysed by 
chemiluminescent immunoassay (Immulite2000, 
Siemens, Germany [14]. Insulin resistance was 
determined by the Homeostasis Model Insulin 
Resistance (HOMA-IR) is calculated as the product of 
the fasting plasma insulin level (IU/mL) and the fasting 
plasma glucose level (mmol/L), divided by 22.5 [15]. 
 
Statistical analysis 
Statistical presentation and analysis of the 
results were carried out using SPSS software version 
17, SPSS Inc., Chicago, IL, USA. Statistical tests 
included chi-square test, and Student's t-tests were 
used. P<0.05 was considered to indicate a statistically 
significant difference. 
The Hardy-Weinberg equilibrium of 
polymorphism was obtained by Fisher’s exact test, 
and the distribution of the genotypes among 
participant groups were tested by the Chi-square test 
or Fisher’s exact test. All continuous variables, 
including age anthropometric and metabolic indices, 
were expressed as means (standard deviation). 
Due to the low frequency of the homo ygous 
Ala Ala genotype, we divided genotypes into two 
categories: Pro/Pro and combined genotypes group 
(Pro/Ala+Ala/Ala). For calculation of risk, Odd ratio 
(OR) and 95% confidence interval (CI) was calculated. 
 
 
Results 
 
Table 1 shows the clinical characteristics and 
biochemical variables for the women with PCOS and 
controls. There were significant increase in BMI, 
WHR, systolic blood pressure (SBP), diastolic blood 
pressure (DBP), LH/FSH, fasting insulin, HOMA-IR, 
TG, TC and LDL-C in PCOS group as compared with 
control group (P<.05 for all) 
The allele and genotype distributions of the 
PPARG Pro12Ala polymorphism for the PCOS and 
the control groups are presented in Table 2. They 
were consistent with the Hardy-Weinberg equilibrium. 
The distribution of the PPARG Pro12Ala alleles and 
genotypes showed statistically significant difference 
between PCOS and controls (p = 0.03). The 
frequency of polymorphic allele Ala was significantly 
higher in PCOS than controls (OR = 2.01, p = 0.01). 
 
Table 1: Clinical and biochemical characteristics in PCOS 
patients and controls 
Variable 
 
PCOS Controls P 
 
Age (years) 24 ± 2.3 23 ± 2.5 0.78 
BMI (kg/m^
2
) 30.12 ± 4.8 23.2 ± 5.9 0.02 
WHR 0.99 ± 0.07 0.76 ± 0.09 0.03 
SBP (mmHg) 138.5 ± 7.3 110.2 ± 6.2 0.05 
DBP(mmHg) 89.6 ± 9.2 74 ± 11.3 0.04 
LH/FSH 1.61 ± 0.83 0.71 ± 0.96 0.03 
FBI (μU/ml) 11.20 ±  0.45 8.20 ±  0.80 0.04 
HOMA-IR 3.9 ± 0.99 2.81 ± 1.01 0.05 
Triglycerides (mg/dl) 120.61 ± 8.29 113.65 ± 9.69 0.03 
Total cholesterol (mg/ dl) 134.71 ± 7.81 90.71 ± 6.45 0.04 
LDL-C (mg/dl) 130.61 ± 11.32 100.71 ± 15.81 .002 
LH, luteinizing hormone/ FSH, stimulating follicle hormone, Values are mean (standard 
deviation).  
 
Table 3 shows clinical, biochemical 
characteristics and anthropometric parameters in 
controls according to PPARG Pro12Ala 
polymorphism. No significant differences were found 
in all biochemical and anthropometric parameters 
between carriers and non-carriers of Ala polymorphic 
allele.  
Table 2: Distribution of PPARG Pro12Ala polymorphism in 
PCOS patients and controls 
 Allele (%)  Genotype (%) 
Groups 
Pro 
N (%) 
Ala 
N (%) 
P 
 
OR 
95% CI 
Pro/Pro 
N (%) 
Pro/Ala 
N (%) 
Ala/Ala 
N (%) 
P 
PCOS (n=100) 162 (81) 38(19) 
0. 01 
2.01 
(1.17-3.47) 
68 (70) 26 (26) 6 (6) 
0.03 
Controls (n=120) 215 (89.58) 25 (10.14) 96 (80) 23 (19.66) 1 (0.8) 
a
χ
2
 test, PPARG, peroxisome proliferator-activated receptor gamma gene; PCOS, 
polycystic ovary syndrome. 
 
In PCOS group the carriers of variant allele 
(Pro/Ala + Ala/Ala) showed significantly higher values 
of systolic and diastolic blood pressure, waist 
circumference, waist to hip ratio, sum of skin folds, 
fasting blood glucose, fasting blood insulin, HOMA-IR, 
triglycerides, total cholesterol, low-density lipoprotein 
compared to the carriers of the wild type Pro alleles 
(Table 4). 
Table 3: Clinical, biochemical characteristics and 
anthropometric parameters in control group according to 
PPARG Pro12Ala polymorphism 
  
Pro/Ala + Ala/Ala 
Mean (± SD) 
 
Pro/Pro 
Mean (± SD) 
Age (years) 23 ± 2.3 22 ± 2.5 
BMI (kg/m
2
) 23.12 ± 7.8 24.2 ± 8.9 
Systolic  BP (mmHg) 125.3 ± 10.3 116.2 ± 9.2 
Diastolic BP(mmHg) 76.6 ± 9.2 74 ± 11.3 
MUAC (cm) 26.9 ± 5.3 26.5 ± 2.4 
WC (cm) 90.1 ± 9.5 85.39 ± 7.7 
Hip circumference (cm) 121.59 ± 9.8 120.33 ± 8.5 
WHR 0.81 ± 0.07 0.86 ± 0.09 
Sum SF (mm) 98.6 ± 11.9 99.19 ± 12.4 
FBG (mg/dl) 105.52 ± 5.22 96.52 ± 6. 22 
FBI (μU/ml) 10.20 ±  0.75 8.20 ± 0.80 
HOMA-IR 2.3 ± .99 2.88 ± 1.01 
Triglycerides (mg/dl) 114.41 ± 10.29 115.65 ± 11.61 
Total cholesterol (mg/ dl) 114.71 ± 11.81 119.71 ± 10.45 
LDL-C (mg/dl) 112.61 ± 21.38 113.71 ± 25.89 
BMI: Body mass index; WHR: Waist to hip ratio; (HOMA-IR): Homeostasis Model Insulin 
Resistance; Sum SF: the sum of skin folds, FBG: fasting blood glucose; FBI: fasting blood 
insulin, Values are mean (standard deviation). 
 
Discussion 
 
The discrepancy has been found between 
numerous studies that have investigated the 
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association between PPARG Pro12Ala polymorphism 
and PCOS [2, 16, 17]. In our study, a significant 
association was found between PCOS and PPARG 
Pro12Ala polymorphism which is in agreement with 
the previous studies supposed its predisposing role in 
PCOS etiopathogenesis [10, 17-19]. Moreover, 
ethnicity differences in the involvement of this 
polymorphism have also been suggested by He et al., 
2012 [2].  
Table 4: Clinical, biochemical and anthropometric 
characteristics in women with PCOS patients according to 
PPARG Pro12Ala polymorphism 
  
Pro/Ala + Ala/Ala 
Mean (± SD) 
 
Pro/Pro 
Mean (± SD) 
Age (years) 23 ± 2.8 22 ± 2.6 
BMI (kg/m
2
) 29.12 ± 2.8 30.1 ±  2.9 
Systolic  BP (mmHg) 150.3 ± 10.3** 116.2 ± 9.2 
Diastolic BP (mmHg) 96.6 ± 9.2* 74 ± 8.3 
MUAC (cm) 31.9 ± 5.3 30.5 ± 2.4 
WC (cm) 113.1 ± 15.5** 74.39 ± 7.7 
Hip circumference (cm) 123.59 ± 9.8 120.33 ± 8.5 
WHR 0.91 ± 0.07 ** 0.76 ± 0.09 
Sum SF (mm) 156.6 ± 11.9** 89.19 ± 14.4 
FBG (mg/dl) 145.52 ± 5.22 ** 96.52 ± 8. 22 
FBI (μU/ml) 18.20 ± 0.65 *** 8.20 ± 0.85 
LH/FSH 1.61 ± 0.53 1.51 ± 0.46 
HOMA-IR 6.3 ± 0.99 *** 2.88 ± 1.29 
Triglycerides (mg/dl) 144.41 ± 13.29 *** 115.65 ± 20.61 
Total cholesterol (mg/ dl) 184.71 ± 13.81 ** 124.71 ± 10.81 
LDL-C (mg/dl) 162.61 ± 21.381 ** 113.71 ± 25.89 
BMI: Body mass index; WHR: Waist to hip ratio; Sum SF: the sum of skin folds; HOMA-IR: 
Model Insulin Resistance. *P<0.05, ** P<0.01***, P <.001 (P value for t-test). 
 
Obesity and insulin resistance are very 
common features in PCOS [20]. The PPARG 
Pro12Ala polymorphism was examined for its potential 
effect on obesity in PCOS cases as it is substantially 
expressed in adipose tissue. The data of the present 
study showed that carriers of Ala allele had 
statistically significant higher values of BMI waist 
circumference, waist to hip ratio and sum of skin folds 
than on- carriers in PCOS group.  
The PPARG plays an important role in 
adipose tissue metabolism, and Pro12Ala 
polymorphism has been reported to be associated 
with abdominal obesity in patients with metabolic 
dysfunction [21]. A positive correlation between 
polymorphism and BMI has been found in European 
and Asian populations [22]. In meta-analysis study 
[23], the correlation between this polymorphism and 
BMI has been found only in the subgroup of BMI ≥ 27 
kg/m^2 where Ala carriers had higher BMI than non-
carriers. Previous studies reported no apparent effect 
of the PPARG Pro12Ala genotype on BMI in PCOS 
patients [18, 24-27]. 
Furthermore, in the present study, we 
investigated the possible association of the PPARG 
Pro12Ala polymorphism with different metabolic 
parameters in PCOS women. We observed 
significantly higher values of blood pressure, fasting 
blood glucose, fasting blood insulin, and HOMA-IR 
and lipid parameters in the carriers of variant allele 
than cases with the wild type.  
PPARG is vital in the manifestation of main 
genes tangled in adipose tissue, lipid and glucose 
metabolism, insulin sensitization, adipokine 
construction and inflammation [28]. Some studies 
reported the association of Pro12Ala polymorphism 
and fasting insulin levels [16, 29, 30] However, others 
[18, 26, 27, 31, 32] reported no associations. 
Moreover, other study showed lower insulin levels in 
carriers of a polymorphic allele in both PCOS cases 
and controls and this effect was not pronounced in 
investigating the PCOS patients alone. Similarly, 
some studies reported that the Pro12Ala 
polymorphism could cause lower insulin levels but 
showing no effect on HOMA-IR in PCOS patients [17, 
29].  
Some factors have been proposed to explain 
such a conflict between studies such as the variations 
in the genetic background of the population studied 
and gene-gene interaction plus the gene-envi-
ronmental interactions [30, 33, 34]. Luan et al., 2006 
demonstrated that the consumption of a diet with a 
low polyunsaturated to saturated fat ratio was 
associated with lower insulin levels and BMI in 
polymorphic allele carriers compared to those with the 
wild genotype [34]. An intersection between the 
genetic basis of PCOS and T2D in addition to the 
epidemiological evidence suggested that genes 
involved in gonadotropin secretion and insulin 
signalling may act in a common pathway or network 
leading to the PCOS phenotype. 
The previous studies derived from European 
population reported that the metabolic parameters 
seemed to be different in PCOS patients with different 
ethnic descents [35-38]. The present study observed 
significantly higher abnormal metabolic components in 
the Ala carries compared to the Pro/Pro carriers, 
confirming the genetic effects of Pro12Ala on 
metabolic parameters in Egyptian PCOS women. 
Therefore, PPARG Pro12Ala gene polymorphism can 
be used as the biomarkers for early diagnosis and 
clinic prediction of metabolic risk in PCOS. Some 
studies reported that improvement in insulin sensitivity 
is predominantly observed only in lean subjects [23, 
33, 39-42]. It appears that obesity may mask the 
protective effect of the Ala allele [42]. Free fatty acids 
that are generated in the process of nutrition and 
metabolism are natural ligands for PPARG. The high 
frequency of the PPARG Pro12Ala polymorphism may 
explain why the PCOS exhibited high levels of fasting 
insulin and HOMA-IR as well as other abnormal 
metabolic risk parameters.  
In conclusion, the PPARG Pro12Ala 
polymorphism might contribute to increased risk of 
PCOS in Egyptian women, and it could be considered 
as a biomarker for early diagnosis and clinic prediction 
of related abnormal metabolic parameters. 
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